TOCILIZUMAB IN THE TREATMENT OF CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS: ANALYSIS OF FACTORS INFLUENCING THE THERAPY EFFICIENCY IN THE LONG TERM
The introduction of tocilizumab - a drug that blocks interleukin 6 - into the practice of pediatric rheumatologists is an important achievement in the treatment of systemic juvenile arthritis (SJA). Objective: Our aim was to identify factors associated with the level of treatment response and safety...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Kitap |
| Baskı/Yayın Bilgisi: |
"Paediatrician" Publishers LLC,
2015-04-01T00:00:00Z.
|
| Konular: | |
| Online Erişim: | Connect to this object online. |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
| Yer Numarası: |
A1234.567 |
|---|---|
| Kopya Bilgisi 1 | Kütüphanede |